Actionable news
0
All posts from Actionable news
Actionable news in LBIO: LION BIOTECHNOLOGIES Inc COMMON STOCK,

Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL in Bladder, Lung, Breast and HPV-Associated Cancers

NEW YORK, Oct. 7, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has obtained an exclusive, worldwide license from the National Institutes of Health (NIH) to develop and commercialize TIL therapy in four additional tumor indications. Under the agreement, the NIH has granted Lion exclusive rights to certain patents to develop TIL in the treatment of bladder, lung, breast and HPV-associated cancers, including cervical and head and neck.

The agreement was executed as an amendment to Lion's existing exclusive licensing agreement with the NIH for the development and commercialization of TIL in the treatment of metastatic melanoma. As consideration for the license, Lion will make an upfront...


More